# Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

> **NCT02724319** · — · COMPLETED · sponsor: **University of Florida** · enrollment: 1000 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** SpartanRX

## Key facts

- **NCT ID:** NCT02724319
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-11-20
- **Final completion:** 2021-12-31
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724319, "Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02724319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*